237 related articles for article (PubMed ID: 9347381)
1. The influence of lithium on fluvoxamine therapeutic efficacy and pharmacokinetics in depressed patients on combined fluvoxamine-lithium therapy.
Miljković BR; Pokrajac M; Timotijević I; Varagić V
Int Clin Psychopharmacol; 1997 Jul; 12(4):207-12. PubMed ID: 9347381
[TBL] [Abstract][Full Text] [Related]
2. [Comparison of the effectiveness of two treatment strategies in inpatients with a depressive disorder. A double-blind study of imipramine followed by lithium addition versus fluvoxamine followed by lithium addition].
Birkenhäger TK; van den Broek WW; Mulder PG; Bruijn JA; Moleman P
Tijdschr Psychiatr; 2006; 48(4):271-81. PubMed ID: 16955991
[TBL] [Abstract][Full Text] [Related]
3. Lithium addition in antidepressant-resistant depression: effects on platelet 5-HT, plasma 5-HT and plasma 5-HIAA concentration.
Birkenhäger TK; van den Broek WW; Fekkes D; Mulder PG; Moleman P; Bruijn JA
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1084-8. PubMed ID: 17467132
[TBL] [Abstract][Full Text] [Related]
4. A comparative study of the efficacy and safety profiles between fluvoxamine and nortriptyline in Japanese patients with major depression.
Otsubo T; Akimoto Y; Yamada H; Koda R; Aoyama H; Tanaka K; Mimura M; Nakagome K; Kamijima K
Pharmacopsychiatry; 2005 Jan; 38(1):30-5. PubMed ID: 15706464
[TBL] [Abstract][Full Text] [Related]
5. Comparison of short-term venlafaxine versus lithium monotherapy for bipolar II major depressive episode: a randomized open-label study.
Amsterdam JD; Shults J
J Clin Psychopharmacol; 2008 Apr; 28(2):171-81. PubMed ID: 18344727
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacokinetics of fluvoxamine: applications to dosage regimen design.
DeVane CL; Gill HS
J Clin Psychiatry; 1997; 58 Suppl 5():7-14. PubMed ID: 9184622
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic fluvoxamine-clomipramine interaction with favorable therapeutic consequences in therapy-resistant depressive patient.
Conus P; Bondolfi G; Eap CB; Macciardi F; Baumann P
Pharmacopsychiatry; 1996 May; 29(3):108-10. PubMed ID: 8738315
[TBL] [Abstract][Full Text] [Related]
8. Concentration-response relationship for fluvoxamine using remission as an endpoint: a receiver operating characteristics curve analysis in major depression.
Suzuki Y; Fukui N; Sawamura K; Sugai T; Watanabe J; Ono S; Inoue Y; Ozdemir V; Someya T
J Clin Psychopharmacol; 2008 Jun; 28(3):325-8. PubMed ID: 18480690
[TBL] [Abstract][Full Text] [Related]
9. Low dosage lithium augmentation in venlafaxine resistant depression: an open-label study.
Alevizos B; Alevizos E; Leonardou A; Zervas I
Psychiatriki; 2012; 23(2):143-8. PubMed ID: 22796912
[TBL] [Abstract][Full Text] [Related]
10. [Maprotiline versus fluvoxamine: comparison of their effects on the hypothalamo-hypophyseal-thyroid axis].
De Mendonça Lima CA; Vandel S; Bonin B; Bechtel P; Carron R
Encephale; 1997; 23(1):48-55. PubMed ID: 9172968
[TBL] [Abstract][Full Text] [Related]
11. Time-dependent clearance decrements of fluvoxamine in depressed inpatients: a clinical evaluation.
van den Broek WW; Birkenhäger TK; Mulder PG; Mathot RA; Bruijn JA; Moleman P
J Clin Psychopharmacol; 2007 Apr; 27(2):231-3. PubMed ID: 17414260
[No Abstract] [Full Text] [Related]
12. Adjunctive lithium carbonate in nortriptyline-resistant elderly depressed patients.
Zimmer B; Rosen J; Thornton JE; Perel JM; Reynolds CF
J Clin Psychopharmacol; 1991 Aug; 11(4):254-6. PubMed ID: 1918424
[TBL] [Abstract][Full Text] [Related]
13. Effects of imipramine, fluvoxamine and depressive mood on autonomic cardiac functioning in major depressive disorder.
Volkers AC; Tulen JH; van den Broek WW; Bruyn JA; Passchier J; Pepplinkhuizen L
Pharmacopsychiatry; 2004 Jan; 37(1):18-25. PubMed ID: 14750044
[TBL] [Abstract][Full Text] [Related]
14. Effect of antacid on the bioavailabiity of lithium carbonate.
Goode DL; Newton DW; Ueda CT; Wilson JE; Wulf BG; Kafonek D
Clin Pharm; 1984; 3(3):284-7. PubMed ID: 6428800
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and efficacy of fluvoxamine and amitriptyline in depression.
Vezmar S; Miljkovic B; Vucicevic K; Timotijevic I; Prostran M; Todorovic Z; Pokrajac M
J Pharmacol Sci; 2009 May; 110(1):98-104. PubMed ID: 19444001
[TBL] [Abstract][Full Text] [Related]
16. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study.
Erzegovesi S; Guglielmo E; Siliprandi F; Bellodi L
Eur Neuropsychopharmacol; 2005 Jan; 15(1):69-74. PubMed ID: 15572275
[TBL] [Abstract][Full Text] [Related]
17. Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial.
Jahn H; Schick M; Kiefer F; Kellner M; Yassouridis A; Wiedemann K
Arch Gen Psychiatry; 2004 Dec; 61(12):1235-44. PubMed ID: 15583115
[TBL] [Abstract][Full Text] [Related]
18. Quetiapine augmentation of treatment-resistant depression: a comparison with lithium.
Dorée JP; Des Rosiers J; Lew V; Gendron A; Elie R; Stip E; Tourjman SV
Curr Med Res Opin; 2007 Feb; 23(2):333-41. PubMed ID: 17288688
[TBL] [Abstract][Full Text] [Related]
19. Serum concentrations of fluvoxamine and clinical effects. A prospective open clinical trial.
Härtter S; Wetzel H; Hammes E; Torkzadeh M; Hiemke C
Pharmacopsychiatry; 1998 Sep; 31(5):199-200. PubMed ID: 9832352
[TBL] [Abstract][Full Text] [Related]
20. Orphan nuclear receptor Rev-erb alpha gene (NR1D1) and fluvoxamine response in major depressive disorder in the Japanese population.
Kishi T; Kitajima T; Ikeda M; Yamanouchi Y; Kinoshita Y; Kawashima K; Okochi T; Ozaki N; Iwata N
Neuropsychobiology; 2009; 59(4):234-8. PubMed ID: 19571598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
